Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Captain ‘Wild’ Bill Wichrowski, known for his role on Discovery Channel’s Deadliest Catch, has provided an encouraging update on his battle with prostate cancer. In a recent statement, he shared that ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

An emergency doctor has highlighted three “worrying” symptoms that could indicate a deadly cancer that kills around 12,000 ...

Testosterone recovery was associated with improved OS in patients with high-risk prostate cancer treated with ADT and radiotherapy.

An emergency physician has pinpointed a trio of "worrying" symptoms that might signal a lethal cancer accountable for nearly ...